1

2
Elizabeth Janet Pease, Emma Jane Williams, Robert Hugh Bradbury, Stuart Eric Pearson: 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents. AstraZeneca, Morgan Lewis & Bockius, January 4, 2005: US06838464 (86 worldwide citation)

Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (C ...


3
Berg Stefan, Hedström Johan, Hellberg Sven, Malmberg Johan: 2-aminopyrimidin-4-ones and their use for treating or preventing aβ-related pathologies. Astrazeneca, Astex Therapeutics, Berg Stefan, Hedström Johan, Hellberg Sven, Malmberg Johan, ASTRAZENECA, October 11, 2007: WO/2007/114771 (74 worldwide citation)

This invention relates to novel compounds having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive i ...


4

5
Derek J Shaw, Brian R Law: Automatically operable safety shield system for syringes. AstraZeneca, Fish & Richardson P C, October 10, 2006: US07118552 (66 worldwide citation)

An automatically operable safety shield system for use with a syringe, the safety shield system including an holder having proximal and distal portions and defining an enclosure into which the syringe may be inserted, an outer shield having proximal and distal portions, mounted outwards from the inn ...


6
Andrew Peter Thomas, Nicholas John Newcombe, David William Heaton: Pyrimidine derivatives. AstraZeneca, Morgan Lewis & Bockius, June 21, 2005: US06908920 (66 worldwide citation)

Compounds of formula (I), wherein R1, p, R2, q, R3 and R4 are defined within, and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle in ...


7
Foote Kevin Michael, Griffen Edward Jolyon: Indole derivatives. Astrazeneca, Astrazeneca, Foote Kevin Michael, Griffen Edward Jolyon, GLOBAL INTELLECTUAL PROPERTY, November 29, 2007: WO/2007/135398 (66 worldwide citation)

The invention concerns indole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of Ring A, m, R1, R2, n, R3 and G1 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and the ...


8
Kettle Jason Grant, Read Jon, Leach Andrew, Barlaam Bernard Christophe, Ducray Richard, Lambert Van Der, Brempt Christine Marie Paul: Pyrimidine derivatives. Astrazeneca, Astrazeneca, Kettle Jason Grant, Read Jon, Leach Andrew, Barlaam Bernard Christophe, Ducray Richard, Lambert Van Der, Brempt Christine Marie Paul, GLOBAL INTELLECTUAL PROPERTY, August 2, 2007: WO/2007/085833 (65 worldwide citation)

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing t ...


9
Hans Carlsson, Anette Larsson, Erik Söderlind: Antigen delivery system and method of production. AstraZeneca, White & Case, January 4, 2005: US06838089 (63 worldwide citation)

The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protei ...


10
Allan Dagsland, Risto Virtanen: Inhalation device. AstraZeneca, Fish & Richardson P C, December 5, 2006: US07143764 (61 worldwide citation)

A powder inhaler for administering powder by inhalation which includes: an inhaler body having an opening therein; an inhalation unit disposed in the inhaler body, the inhalation unit including an inhalation channel through which powder is in use inhaled; a dosing unit for providing a dose of powder ...